Genetic optical therapy restores object recognition in blind patients

Blindness caused by retinitis pigmentosa was partially reversed in patients who received a treatment based on research that won the 2026 Nobel Prize in Medicine, in a small trial demonstrating the potential of this innovative approach.

Known as optogenetic therapy, the treatment combines gene therapy to make remaining retinal ganglion cells light-sensitive with specialized glasses that deliver light to stimulate these cells.

Each of the 10 trial participants received an injection in one eye carrying a genetic code for the protein Crimson.R, a light-sensitive protein manufactured by GenSight Biologics.

Patients then wore glasses that captured visual information and converted it into light patterns at wavelengths that activate the Crimson.R protein in the modified retinal cells, sending these light patterns back into the eye.

Seven patients became more light-sensitive, and six achieved clinically significant improvements, such as the ability to detect the presence of an object, locate it, and accurately reach toward it. Clinical significance refers to the practical or tangible benefit of a treatment in patients’ lives.

Researchers reported in the New England Journal of Medicine that a serious adverse event occurred immediately after injection but resolved within minutes.

The researchers stated that although larger studies are needed to definitively prove the efficacy of Crimson.R and the glasses, the results show that it is possible to make remaining retinal ganglion cells respond to light and transmit visual information to the brain, even in very advanced stages of blindness.

Dr. José-Alain Sahel of the University of Pittsburgh said in a statement, “Even among those with severe vision loss, the visual system retains a remarkable capacity to process new information.” Sahel is the study’s lead author.